Order Article Reprints

Watanabe S, Sakai K, Matsumoto N, Koshio J, Ishida A, Abe T, Ishikawa D, Tanaka T, Aoki A, Kajiwara T, et al. Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501). Cancers. 2023; 15(1):204. https://doi.org/10.3390/cancers15010204

Watanabe, Satoshi, Kazuko Sakai, Naoya Matsumoto, Jun Koshio, Akira Ishida, Tetsuya Abe, Daisuke Ishikawa, Tomohiro Tanaka, Ami Aoki, Tomosue Kajiwara, and et al. 2023. "Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)" Cancers 15, no. 1: 204. https://doi.org/10.3390/cancers15010204

Watanabe, S., Sakai, K., Matsumoto, N., Koshio, J., Ishida, A., Abe, T., Ishikawa, D., Tanaka, T., Aoki, A., Kajiwara, T., Koyama, K., Miura, S., Goto, Y., Sekiya, T., Suzuki, R., Kushiro, K., Fujisaki, T., Yanagimura, N., Ohtsubo, A., ... Kikuchi, T. (2023). Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501). Cancers, 15(1), 204. https://doi.org/10.3390/cancers15010204